We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:
A company with a novel proprietary first-in-class bispecific antibody immunotherapy platform for solid and liquid tumors, with four clinical candidates, the most advanced in Ph II trials, available for licensing.
A company with a novel, proprietary, first-in-class humanized monoclonal antibody for the treatment of fibrotic diseases and inflammatory disorders, available for licensing.
A company with several targeted clinical-stage products based on their ceremide technology for orphan oncology indications, including PTCL, CTCL, with Ph II data, available for licensing.
A company with a novel treatment for short bowel syndrome, an orphan GI disorder with composition of matter, available for licensing.
A company with 4 novel, best in class bispecific and monoclonal antibodies targeting HGF, synergistic with cMET for the treatment of gastric and liver cancer (Ph II ready, with 30KG of frozen GMP material) , FGF2 to treat HCC, Death receptors (DR4 and DR5) and high potency HuVE1 anti-VEGF mAb and HuA2T mAb to angiopoietin-2 (ang-2), available for licensing.
A company currently enrolling a Ph III trial to treat an orphan GI disorder, available for licensing.